Get this wrong and everything downstream falls apart
Researchers have found diseases including cardiovascular disease, non-alcoholic fatty liver disease, diabetic chronic kidney disease, osteoarthritis, autoimmune disease, alcohol use disorder and more could be positively impacted by GLP-1RA therapy
10.1124/jpet.109.160531 181
sleepfoundation.org CMS
In this evolving landscape, we remain committed to providing safe, effective, and personalized weight loss solutions
Some researchers suspect that reducing GLP-1 medication dosage through a slow, sustained taper (instead of rapidly decreasing dosage over a short period of time, or stopping them suddenly altogether), could help some patients prevent rebound weight gain, but well need more data to confirm this with any confidence or say why it might be the case